Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.13%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-07-16 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
16
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-15 Otsuka Holdings Co.,Ltd. “Announcement of the new domestic launch of the PI3Kα inhibitor "Heitzexin® Tablets 10mg".”
16
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-15 Otsuka Holdings Co.,Ltd. “Otsuka Group to introduce its first battery storage system in the Hokkaido area – aiming to maximize renewable energy use and stabilize power supply, thereby promoting both business growth and environmental responsibility.”
16
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-15 Eisai Co.,Ltd. “The results of the "Rekenbi®" real-world clinical LEADER study were presented at AAIC 2026—among patients with early-stage Alzheimer's disease who received treatment for an average of 17 months, over 75% maintained their disease stage and approximately 7% showed improvement—these real-world clinical data support the long-term benefits of continued administration of "Rekenbi" and provide important insights into the actual treatment practices in daily clinical practice.”
16
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-15 Shionogi & Co.,Ltd. “Pharmaceutical x Data Science Meetup 2026: Opportunities for those from outside the industry! Lectures and career counseling on cutting-edge AI and data utilization in the pharmaceutical industry.”
16
Jul
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-07-15 Sumitomo Pharma Co.,Ltd. “The creation of the regenerative medicine product "Amshepri" won the "10th Bioindustry Award".”
15
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-14 Otsuka Holdings Co.,Ltd. “Otsuka Holdings has been selected as a constituent stock of the ESG investment index "FTSE4Good Index Series," "FTSE JPX Blossom Japan Index," and "FTSE JPX Blossom Japan Sector Relative Index."”
15
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”
15
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has received approval from the U.S. FDA as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy. LEQEMBI IQLIK is scheduled to be launched in the U.S. in late August 2026 as an initial treatment.”
14
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-13 Otsuka Holdings Co.,Ltd. “Notice of price revisions for some products – effective for deliveries from September 1st, 2026 (Tuesday).”
14
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-13 Eisai Co.,Ltd. “Clinical data supporting the efficacy and safety of the "Rekenbi®" subcutaneous autoinjector, comparable to intravenous formulations, in early Alzheimer's disease were presented at AAIC 2026. New clinical and real-world data support a subcutaneous treatment pathway from initial therapy to ongoing therapy, contributing to improved convenience for patients and care partners.”
14
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-13 Shionogi & Co.,Ltd. “Regarding the signing of a joint research agreement with Nagasaki University and MMV aimed at creating new malaria preventive drugs, and the selection of the project by the GHIT Fund.”
14
Jul
Astellas Pharma Inc. JP3942400007
2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”
11
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-10 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory expands manufacturing capacity for intravenous fluid products in North America to improve supply stability and promote the availability of DEHP-free intravenous fluid containers.”
11
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-10 Otsuka Holdings Co.,Ltd. “Otsuka Holdings publishes its "Integrated Report 2026".”
07
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-06 Otsuka Holdings Co.,Ltd. “Astex, a UK subsidiary, has announced an exclusive research partnership and licensing agreement with Genentech for its breast cancer treatment project.”
04
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-03 Shionogi & Co.,Ltd. “We have posted the video and transcript of the 161st Ordinary General Meeting of Shareholders.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “UCL and Eisai extend joint research agreement to accelerate the creation of treatments for neurodegenerative diseases.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “At the Alzheimer's Disease Association International Conference 2026 (AAIC2026), the Alzheimer's disease portfolio was presented through more than 50 presentations.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
01
Jul
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-30 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspring (application for thyroid eye disease accepted by the U.S. FDA).”